Overview

Study of Epcoritamab in Relapsed and Refractory Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab

Status:
NOT_YET_RECRUITING

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this phase 2 study is to evaluate the efficacy and safety of epcoritamab in subjects with relapsed or refractory primary diffuse large B-cell lymphoma of the Central Nervous System treated with rituximab and lenalidomide.

Phase:

PHASE2

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Collaborator:

AbbVie